Drugs / FGF-1 141
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00916292 | Nov 2012 → Sep 2013 | ulcer of lower limbs | Phage Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FGF-1 141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00916292 ↗ |
| Known as | Human Fibroblast Growth Factor-1 | “Human Fibroblast Growth Factor-1 (FGF-1)” NCT00916292 ↗ |